Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Long Ming
 -- 1884 2022-04-18 11:47:48 |
2 revised
Camila Xu
 Meta information modification 1884 2022-04-19 04:03:33 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ming, L.; Hossain, M.S.; Goh, K.W.; Hadi, M.; Karuniawati, H.; Mohammed, A.; Urbi, Z.; Ooi, D.J.; John, A.; Lim, Y.C.; et al. Colorectal Cancer Development. Encyclopedia. Available online: https://encyclopedia.pub/entry/21875 (accessed on 22 November 2024).
Ming L, Hossain MS, Goh KW, Hadi M, Karuniawati H, Mohammed A, et al. Colorectal Cancer Development. Encyclopedia. Available at: https://encyclopedia.pub/entry/21875. Accessed November 22, 2024.
Ming, Long, Md. Sanower Hossain, Khang Wen Goh, Muhammad Hadi, Hidayah Karuniawati, Aj Mohammed, Zannat Urbi, Der Jiun Ooi, Akbar John, Ya Chee Lim, et al. "Colorectal Cancer Development" Encyclopedia, https://encyclopedia.pub/entry/21875 (accessed November 22, 2024).
Ming, L., Hossain, M.S., Goh, K.W., Hadi, M., Karuniawati, H., Mohammed, A., Urbi, Z., Ooi, D.J., John, A., Lim, Y.C., & , . (2022, April 18). Colorectal Cancer Development. In Encyclopedia. https://encyclopedia.pub/entry/21875
Ming, Long, et al. "Colorectal Cancer Development." Encyclopedia. Web. 18 April, 2022.
Colorectal Cancer Development
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers14071732

Colorectal cancer (CRC) is a disorder that occurs exclusively in the colon or rectum and is caused by the colon’s aberrant proliferation of glandular epithelial cells.

colon cancer oncology chemotherapy epidemiology

1. Introduction

Colorectal cancer (CRC), which comprises colon and/or rectum cancer, represents a significant health problem as the world’s third most commonly diagnosed and second most fatal cancer globally [1]. Approximately 9.4% of cancer-related deaths were due to CRC in 2020 [2]. However, in light of the significant increase in the number of identified cases in the older population, it is estimated that the global incidence of CRC will more than double by 2035, with the most significant increase occurring in less developed nations [3].
CRC is a disorder that occurs exclusively in the colon or rectum and is caused by the colon’s aberrant proliferation of glandular epithelial cells. There are three principal types of CRC: Sporadic, hereditary, and colitis-associated. The number of CRC cases is increasing globally day by day. Both environmental and genetic factors determine the risk of developing CRC. In addition, the risk of developing CRC in patients with long-standing ulcerative colitis and Crohn’s disease increases with age [4]. Multiple studies have demonstrated that risk factors for CRC include diet and lifestyle, family history, and chronic inflammation [5].
However, the most effective method of preventing CRC and reducing CRC-related deaths across the population is screening average-risk individuals [5]. Therefore, most European countries, Canada, specific regions in North and South America, Asia, and Oceania have initiated population-based screening programs [6]. Eligibility to participate in CRC screening is determined by age and area of residence. The results of microsimulation modeling have shown a downward trend in CRC morbidity and mortality in the United States, attributed to the implementation of screening programs [5]. In addition, population-based screening aims to reveal latent disease among the average-risk population, enabling early-stage interventions and reducing the threat to individuals and/or communities [7].
Screening is particularly appropriate in CRC, as it is not only a common disorder but one thought to be characterized by a gradual development of the adenoma–carcinoma sequence [8]. Although the time taken for an early adenoma to progress to an established CRC is yet unknown, the current evidence suggests it to be no less than ten years [9], offering abundant opportunity for detection via screening followed by treatment. Furthermore, CRC can be prevented by removing colorectal adenomas [10], and the earlier the CRC is detected, the less likely the patient will die [11]. Treatment outcomes are thus positively impacted by interventions along the adenoma–carcinoma pathway. Other effective strategies include identifying and monitoring high-risk populations, including individuals with inflammatory bowel disease, families with hereditary CRC syndrome, individuals whose family history suggests a genetic predisposition to CRC but have no detectable genetic markers, and individuals whose phenotypic appearance indicates high risk. The metabolome helped identify the important biological activities affected by genetic variation [12]. The most frequently used CRC screening methods are fecal occult blood tests (FOBTs) and lower endoscopy [13].
CRC development takes years. Generally, 10 to 15 years is required for a polyp to form a malignant tumor. So, regular screening, detecting, and removing polyps at the early stage is crucial; thereby, CRC can be prevented. Current diagnosis can detect only 40% of CRC cases in the early stages, and CRC might recur following surgery and post-surgery treatment [14]. Chemotherapeutic medications target cancer cells while also harming healthy cells in the environment. Modern chemotherapies acquired resistance in nearly all CRC patients, decreasing anticancer drug efficacy and ultimately leading to chemotherapy failure. Therefore, a comprehensive discussion on the epidemiology, the risk factors, and preventive measurement of CRC based on the updated evidence-based knowledge is crucial to overcome the future challenges of CRC. This research discussed the current global epidemiology, drug resistance, its challenges, risk factors, and preventive and treatment strategies of CRC. Additionally, there is a brief discussion on CRC carcinogenesis and recommendations for preventing and treating CRC.

2. Colorectal Cancer Development

CRC is genetically diverse; however, it can develop through various unique mechanisms. For example, many CRC cells exhibited dozens of somaclonal mutations resulting from the distinct level of gene expression profiles. As a result, CRC is believed to have one of the most incredible mutational loads of any malignancy. Based on the number of somaclonal mutations, CRC can be broadly categorized as hypermutated (more than 12 mutations per 106 bases) or non-hypermutated (fewer than 8.24 mutations per 106 bases) [15]. In addition, a novel categorization system for CRC was developed as a result of parallel efforts to categorize CRC based on gene expression profiles. These classifications have been updated and modified due to integrating data on gene expression profiles with tumor genotypes [15].
CRC develops when epithelial cells acquire a series of genetic or epigenetic changes that enable them to be hyperproliferative [16]. These rapidly developing cells form a benign adenoma, which can advance to cancer and metastasize via several distinct pathways, including microsatellite instability (MSI), chromosomal instability (CIN), and serrated neoplasia [17][18][19]. Adenoma–carcinoma sequence is a term used to describe cancer progression. The traditional pathway is responsible for the vast majority of sporadic CRC cases. Cancer begins as a tiny adenoma that becomes a giant adenoma and, finally, cancer. There is a strong association between this pathway and the development of the chromosomal instability (CIN)-positive subtype (CIN-positive). According to the National Cancer Institute, this model accounts for 10–15% of sporadic CRC. It is defined by development from normal cells to hyperplastic polyp, sessile serrated adenomas, and eventually cancer [13]. This route is typically involved in developing the CpG island methylator phenotype (CIMP)-high subtype, the pathway involved in inflammation. The prolonged inflammation causes normal cells to develop indeterminate dysplasia, which progresses further to low-grade dysplasia, progresses further to high-grade dysplasia, and finally, cancer [13]. Inflammatory bowel illnesses and the widespread use of prophylactic colectomy are responsible for less than 2% of CRC cases worldwide. There are benign precursor lesions accessible and removed in all pathways, albeit more noticeable in the adenoma–carcinoma and serrated pathways [13]. Because they take years to grow into cancer, there is a window of opportunity for secondary prevention of colorectal cancer.
When an adenocarcinoma becomes invasive, it can spread to other body parts via blood and lymphatic arteries (Figure 1). Adenocarcinomas account for roughly 96% of all CRC [20]. However, up to 18 years may pass between developing a polyp and invasive cancer. On average, it takes nine years to form metastasis [21]. Like any other tumor or cancer, CRC is classified by stage 0 (carcinoma in situ) through stage IV (Figure 1).
Figure 1. Colorectal cancer (CRC) stages and development. There are four stages in the development of CRC carcinogenesis: initiation, promotion, progression, and metastasis. The liver is the most common metastatic site, followed by the lung and bone. Although it is difficult to determine the duration required for each stage, decades will likely be required to form CRC. The figure was created using BioRender.com (accessed on 30 December 2021).
Usually, a non-cancerous development results in dysplastic tissue formation (tumor), leading to CRC development once the cells have undergone several abnormal DNA changes. A non-cancerous (benign) soft tissue tumor is a growth that does not spread (metastasize) to other parts of the body. Hyperproliferation causes a (benign) polyp or adenoma to form (stage 0). Ten percent of adenomatous polyps can become malignant, forming an adenocarcinoma that invades the muscularis propria (stage I). The tumor grows in volume and further invades tissue in the serosa (stage II) and visceral peritoneum (stage III). Then, there is the possibility of developing lymphatic or blood vessel metastasis (stage IV) [22]. The stage determines the severity of the disease and the therapy options available [23]. Even though surgery is the standard treatment choice for stages 0–II CRC, stage III CRC requires surgery and adjuvant chemotherapy, and stage IV and recurrent CRC require surgery, chemotherapy, and targeted therapy; however, unfortunately, it has no known certainty established cure until now.

3. Current Global Epidemiology of Colorectal Cancer

According to GLOBOCAN data, in 2020, there were an estimated 19.3 million new cases and 10 million cancer deaths worldwide, of which CRC contributed about 1.93 million (10%) further incidences and 0.94 million (9.4%) deaths (Figure 2a,b). The overall estimated age-standardized global distribution of incidence and mortality of CRC for both sexes and all ages is shown in Figure 3. The incidence and mortality of CRC vary considerably between countries and among world regions. They are also associated with the socioeconomic status of the country. According to the World Bank, the new cases and deaths are more remarkable in areas with higher income levels and lesser in areas with lower income levels.
Figure 2. CRC new cases and deaths in 2020. (a) shows new cases, both sexes and all ages, and (b) shows deaths of both sexes for all age groups. The value shown in % is calculated against the total number of all cancers. The data source is GLOBOCAN [24], taken with permission.
Figure 3. Map showing the global distribution of estimated age-standardized incidence rates (top) and mortality rate (bottom) of CRC in 2020 for both sexes and all ages. (Reproduced from GLOBOCAN [24] with permission).
The incidence and deaths of CRC are increasing in developing countries for both males and females, even though it is significantly high in high-income countries. The upper-middle-income countries accounted for the highest incidences (45.94%) and deaths (49.37%). The higher-income countries recorded fewer incidences (42.43%) than upper-middle-income countries; however, the deaths were significantly lower (36.40%), perhaps due to better treatment facilities (Figure 4). The high-income and upper-middle-income countries covered more than 88 and 85% of incidence and mortality, respectively (Table 1) [25].
Figure 4. World CRC incidence and mortality rates in 2020 (according to income level for all age groups). The data were extracted from GLOBOCAN [24] with permission.
Table 1. World CRC estimated age-standardized incidence and mortality rates in 2020 (all ages).
Population * Incidence (%) Mortality (%)
Upper middle income 887,025 (45.94) 461,511 (49.37)
High income 819,143 (42.43) 340,272 (36.40)
Low middle income 194,954 (10.10) 112,556 (12.04)
Low income 29,542 (1.53) 20,392 (2.18)
Total 1,930,664 934,731
* Data extracted from GLOBOCAN [24] with permission.
In 2020, CRC was the most diagnosed cancer (out of 36 cancers) among men in 18 of the 186 countries worldwide and women in 6 of the 185 countries [25]. However, in 2018, CRC was the most diagnosed among men in 10 of 185 countries, and no country had CRC as the most diagnosed cancer among women [26]. So, the CRC incidence rate has increased to about 10 from 5% in the last two years in men. Women were predominant in 3.24% of countries (Figure 4). CRC is more common among men than women and more than four times more common in high-income countries than low-income countries. The deaths were also about 2.5 times higher in high-income nations than in low-income nations.
In 2020, age-standardized (world) incidence rates per 100,000 of CRC in both sexes were 19.8, with males having a higher incidence rate of 23.4 and females with 16.2, which is almost equal to the incidence of 2018 [25][26]. The death rate in both sexes was 9.1; for men was 11, and for women was 7.2 per 100,000 CRC (Figure 4).
Among CRC, colon cancer was predominant and accounted for 59.5% of new cases, 61.9% of deaths and rectum cancer had 37.9% of incidence and 36.3% mortality for both sexes and all ages (Figure 5). Colon cancer alone stands fifth for new cancer cases and deaths compared to all cancers. In contrast, rectum cancer is the eighth and tenth most severe cancer for incidences and mortality, respectively [25].
Figure 5. World new cases and deaths of colon cancer, rectum cancer, and anus cancer in 2020. (a) New cases and (b) deaths of colon cancer, rectum cancer, and anus cancer. The value is shown in % on top of each column and is calculated against the CRC number in 2020 for both sexes and all ages. Data extracted from GLOBOCAN [24] with permission.

References

  1. WHO. Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer (accessed on 14 July 2021).
  2. Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global Cancer Observatory: Cancer Today. Available online: https://gco.iarc.fr/today (accessed on 14 July 2021).
  3. Papamichael, D.; Audisio, R.A.; Glimelius, B.; de Gramont, A.; Glynne-Jones, R.; Haller, D.; Kohne, C.H.; Rostoft, S.; Lemmens, V.; Mitry, E.; et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015, 26, 463–476.
  4. Triantafillidis, J.K.; Nasioulas, G.; Kosmidis, P.A. Colorectal cancer and inflammatory bowel disease: Epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009, 29, 2727–2737.
  5. Edwards, B.K.; Ward, E.; Kohler, B.A.; Eheman, C.; Zauber, A.G.; Anderson, R.N.; Jemal, A.; Schymura, M.J.; Lansdorp-Vogelaar, I.; Seeff, L.C.; et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116, 544–573.
  6. Navarro, M.; Nicolas, A.; Ferrandez, A.; Lanas, A. Colorectal cancer population screening programs worldwide in 2016: An update. World J. Gastroenterol. 2017, 23, 3632–3642.
  7. Wilson, J.M.; Jungner, Y.G. Principles and practice of mass screening for disease. Bol. Oficina Sanit. Panam. 1968, 65, 281–393.
  8. Morson, B.C. The evolution of colorectal carcinoma. Clin. Radiol. 1984, 35, 425–431.
  9. Winawer, S.J.; Fletcher, R.H.; Miller, L.; Godlee, F.; Stolar, M.H.; Mulrow, C.D.; Woolf, S.H.; Glick, S.N.; Ganiats, T.G.; Bond, J.H.; et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997, 112, 594–642.
  10. Winawer, S.J.; Zauber, A.G.; Ho, M.N.; O’Brien, M.J.; Gottlieb, L.S.; Sternberg, S.S.; Waye, J.D.; Schapiro, M.; Bond, J.H.; Panish, J.F.; et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N. Engl. J. Med. 1993, 329, 1977–1981.
  11. Ciccolallo, L.; Capocaccia, R.; Coleman, M.P.; Berrino, F.; Coebergh, J.W.W.; Damhuis, R.A.M.; Faivre, J.; Martinez-Garcia, C.; Møller, H.; De Leon, M.P. Survival differences between European and US patients with colorectal cancer: Role of stage at diagnosis and surgery. Gut 2005, 54, 268–273.
  12. Garcia-Etxebarria, K.; Clos-Garcia, M.; Telleria, O.; Nafría, B.; Alonso, C.; Iruarrizaga-Lejarreta, M.; Franke, A.; Crespo, A.; Iglesias, A.; Cubiella, J.; et al. Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer. Cancers 2021, 13, 6216.
  13. Keum, N.; Giovannucci, E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 713–732.
  14. ACS. Cancer Facts & Figures. 2020. Available online: https://www.cancer.org/cancer/colon-rectal-cancer/ (accessed on 15 July 2021).
  15. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330.
  16. Testa, U.; Pelosi, E.; Castelli, G. Colorectal cancer: Genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med. Sci. 2018, 6, 31.
  17. Malki, A.; ElRuz, R.A.; Gupta, I.; Allouch, A.; Vranic, S.; Al Moustafa, A.E. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int. J. Mol. Sci. 2020, 22, 130.
  18. Nguyen, H.T.; Duong, H.Q. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol. Lett. 2018, 16, 9–18.
  19. Vogelstein, B.; Fearon, E.R.; Hamilton, S.R.; Kern, S.E.; Preisinger, A.C.; Leppert, M.; Nakamura, Y.; White, R.; Smits, A.M.; Bos, J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319, 525–532.
  20. Pickhardt, P.J.; Kim, D.H.; Pooler, B.D.; Hinshaw, J.L.; Barlow, D.; Jensen, D.; Reichelderfer, M.; Cash, B.D. Volumetric growth rates of small colorectal polyps: Longitudinal investigation of natural history using CT colonography. Lancet Oncol. 2013, 14, 711.
  21. Stryker, S.J.; Wolff, B.G.; Culp, C.E.; Libbe, S.D.; Ilstrup, D.M.; MacCarty, R.L. Natural history of untreated colonic polyps. Gastroenterology 1987, 93, 1009–1013.
  22. NIH. Advances in Colorectal Cancer Research: Stages of Colorectal Cancer. Available online: https://www.nih.gov/research-training/advances-colorectal-cancer-research (accessed on 30 December 2021).
  23. Slattery, M.L.; Edwards, S.L.; Samowitz, W. Stage of colon cancer at diagnosis: Implications for risk factor associations? Int. J. Epidemiol. 1998, 27, 382–387.
  24. GLOBOCAN. Global Cancer Observatory (GCO): Cancer Today. Available online: https://gco.iarc.fr/today/# (accessed on 15 August 2021).
  25. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  26. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Long Ming
,
Md. Sanower Hossain
,
Khang Wen Goh
,
Muhammad Hadi
,
Hidayah Karuniawati
,
aJ Mohammed
,
Zannat Urbi
,
Der Jiun Ooi
,
akbar John
,
Ya Chee Lim
,
View Times: 2.7K
Revisions: 2 times (View History)
Update Date: 19 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback